SKP.L Regulatory News (SKP)

Skyepharma Announces Board Changes

LONDON, ENGLAND, 5 March 2014 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, today announces that John Biles has been appointed a Non-Executive Director, Chairman of the Audit Committee and a member of the Remuneration and Nomination and Governance Committees. Additionally, Jean-Charles Tschudin, who joined the Board as a Non-Executive Director in July 2007, has today been appointed Senior Independent Director.

Mr Biles (66) is Chairman of the Audit Committees of Bodycote PLC, HellermannTyton Group PLC and Sutton and East Surrey Water PLC and is also Senior Independent Director of Bodycote and Sutton and East Surrey Water.

Since 2001 he has served in numerous Non-Executive roles with major companies such as Amey PLC, Charter International PLC, Viridian Group PLC and Hermes Fund Management Limited, in each case also holding the position of Chairman of the Audit Committee. He qualified as a Chartered Accountant with Price Waterhouse & Co, following which he held the position of Financial Director at various subsidiaries of Racal Electronics Plc and then successively Group Finance Director of Chubb Security Plc and FKI Plc. He holds a Bachelor of Sciences Combined Honours degree in Chemistry and Physics from the University of Exeter.

Frank Condella, Chairman of Skyepharma, commented:

"Skyepharma is pleased to be able to announce the appointment of John Biles as a Non-Executive Director, although it is a great pity that it was not possible to have the planned handover from our previous Audit Committee Chairman, Alan Bray, who sadly passed away last week. John brings a broad range of financial and business experience to the Board and its Committees. I look forward to working with him as we leverage our strong platform for future growth and continue to create value for our shareholders."

Commenting on his appointment, Mr Biles said:

"I am delighted to be joining Skyepharma and to lead the Audit Committee. I look forward to working with the Board in furtherance of the Company's future growth."

Listing Rule 9.6.13

A further announcement in compliance with paragraph 9.6.13 of the Listing Rules will be made in due course.

-Ends-

For further information please contact:

About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 15 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharmaceutical as well as specialty pharmaceutical companies. For more information, visit www.skyepharma.com.